Ad
related to: immunosuppressants after kidney transplant patients take phentermine diet
Search results
Results From The WOW.Com Content Network
Mycophenolic acid is an immunosuppressant medication used to prevent rejection following organ transplantation and to treat autoimmune conditions such as Crohn's disease and lupus. [12] [13] Specifically it is used following kidney, heart, and liver transplantation. [13] It can be given by mouth or by injection into a vein. [13]
Calcineurin inhibitors and azathioprine have been linked with post-transplant malignancies and skin cancers in organ transplant recipients. Non-melanoma skin cancer (NMSC) after kidney transplantation is common and can result in significant morbidity and mortality. The results of several studies suggest that calcineurin inhibitors have ...
A novel approach to organ transplantation allowed patients to wean off anti-rejection drugs after two years, according to the results of a phase 3 clinical trial presented Monday.
In general, deliberately induced immunosuppression is performed to prevent the body from rejecting an organ transplant. [3] Additionally, it is used for treating graft-versus-host disease after a bone marrow transplant , or for the treatment of auto-immune diseases such as systemic lupus erythematosus , rheumatoid arthritis , Sjögren's ...
Basiliximab is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation. [3] It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in people with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids ...
Muromonab-CD3 (brand name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant medication given to reduce acute rejection in people with organ transplants. [1] [2] It is a monoclonal antibody targeted at the CD3 receptor, [3] a membrane protein on the surface of T cells.
In transplant patients, skin cancer is 50 to 250 times more common than in the general population, and between 60 and 90% of patients are affected 20 years after transplantation. The use of immunosuppressive medication including azathioprine in organ transplantation has been linked to increased rates of developing skin cancer. [ 51 ]
Thymoglobulin and Atgam are currently licensed for use in the treatment of renal allograft rejection; Atgam is additionally licensed for use in the treatment of aplastic anemia. Both drugs are used in off-label applications, especially as immunosuppression induction agents before and/or during kidney transplantation.